SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

TORONTO -- For some patients with multiple myeloma and their physicians, progression-free survival (PFS) is just as important as overall survival (OS), according to results from a cross-sectional ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer. Darzalex Faspro is the ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Sarah ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...